Phase II Study of the Combination of Blinatumomab and Ponatinib in Patients With Philadelphia Chromosome (Ph)-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL)
Phase of Trial: Phase II
Latest Information Update: 27 Dec 2018
At a glance
- Drugs Blinatumomab (Primary) ; Ponatinib (Primary) ; Cytarabine; Dexamethasone; Dexamethasone; Methotrexate
- Indications Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- 09 Nov 2018 Planned End Date changed from 1 Nov 2024 to 1 Nov 2023.
- 31 Aug 2018 Biomarkers information updated
- 19 Mar 2018 Planned End Date changed from 1 Nov 2023 to 1 Nov 2024.